Panel Intelligence, LLC, April 2008
PCP’s and 31 Cardiologists for 103 respondents
- Fielding Dates: April 1st to April 4th, 2008
Objectives: To determine the impact of the ENHANCE study on Vytorin and Zetia use
Inclusion Criteria
Datamonitor, Nov 2011, Pages: 37
but Niaspan, Zetia and Tricor will create an environment that will make establishing market share for a premium product more challenging than ever.
- GlaxoSmithKline’s prescription formulation of the omega oils
GenericsWeb, Feb 2012
Ezetimibe innovator: MSD (Zetia, Ezetrol); Schering Plough (Zetia, Ezetrol)
Examples of information found in this online report include:
- Includes key patent publications for 7 countries (see list below
GenericsWeb, Feb 2012
Ezetimibe innovator: MSD (Zetia, Ezetrol); Schering Plough (Zetia, Ezetrol)
Examples of information found in this online report include:
- Includes key patent publications for 44 countries (see list below
GenericsWeb, Feb 2012
: Hypercholesterolemia; Sitosterolemia
Ezetimibe innovator: MSD (Zetia, Ezetrol, Inergy); Schering Plough (Zetia, Ezetrol, Inergy); MSP Singapore (Vytorin)
Imagine having your own team of pharmaceutical patent experts
GenericsWeb, Feb 2012
are controlled by a nominated 'company administrator'.
Pipeline Developer is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite. MSD (Zetia, Ezetrol, Inergy
Global Industry Analysts, Inc., April 2010, Pages: 429
Merck’s Cholesterol Pill to Receive FDA Approval in 2013 II-24
Schering-Plough Obtains Approval for Marketing ZETIA® II-24
5. RECENT INDUSTRY ACTIVITY II-25
Abbott and Solvay Group Enter into Definitive
GlobalData, June 2010, Pages: 84
’ patents. Pfizer’s Lipitor, which is a major blockbuster in the dyslipidemia market, is set to expire in 2011 along with Trilipix’s. Zetia, Vyotrin, Simcor, Lescol, Livalo and Lovaza are set to expire
Global Markets Direct, Nov 2010, Pages: 36
+ Zetia
Product Description
Mechanism of Action
R&D Progress
Aegerion Pharmaceuticals, Inc. – Pipeline Analysis
Aegerion Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Espicom Business Intelligence Ltd, Nov 2009, Pages: 186
these losses have emerged from its successful joint venture with Schering-Plough, which has seen Vytorin and Zetia come to market. Vytorin in particular is expected to become a major growth driver, despite
Datamonitor, March 2009, Pages: 163
, completed in 2007
- Assess the diversity of Schering-Ploughs product portfolio in light of forecast declining sales for its recent sales growth driver Zetia/Vytorin
CHAPTER 1 ABOUT THIS PROFILE
Executive
MP Advisors, Feb 2011, Pages: 90
and Otelixizumab
- Syncria Efficacy data
- Pipeline GLP-1 compared to Byetta
Merck: Ripen late stage pipeline
Remicade - JNJ arbitration
Vytorin Zetia - Positive SHARP data should reinstate lost glory
Espicom Business Intelligence Ltd, Aug 2008, Pages: 164
/Asmanex, Avelox and PEG-Intron are all forecast to demonstrate sustained growth into fiscal 2012, offsetting any losses predicted in other major products. Furthermore, Zetia and Vytorin, the key components
